HARVARD BIOSCIENCE INC

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, software, consumables, and services used in life science research, pharmaceutical discovery, bioproduction, and preclinical drug evaluation. The company organizes its product lines into two primary segments: Cellular and Molecular Technologies (CMT) and Preclinical. CMT offerings include electroporation tools, amino acid analyzers, spectrophotometers, high-precision pumps, and microelectrode arrays. The Preclinical segment supplies physiological data acquisition tools such as telemetry systems, respiratory monitors, inhalation chambers, and animal behavior tracking systems. Customers include academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and contract research organizations.

The company operates globally through direct sales and distribution networks across the United States, Europe, and China, with primary manufacturing facilities in the United States, Germany, and Spain. As of December 2025, the organization employs 339 workers across production, commercial, and research operations. It maintains its corporate manufacturing operations in Holliston, Massachusetts, alongside additional facilities in Minneapolis, Germany, the United Kingdom, and Spain.

Summary of the business section of Harvard Bioscience's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 339 employees, including 316 full-time employees.”